BioCentury
ARTICLE | Emerging Company Profile

Euthymics: Balancing act

Euthymics: Correct balance of triple reuptake inhibition will be key in MDD

December 5, 2011 8:00 AM UTC

Euthymics Bioscience Inc. thinks a molecule orphaned by Dov Pharmaceutical Inc. has the right relative ratio of monoamine reuptake inhibition to offer better efficacy and tolerability than marketed antidepressants.

About 60% of MDD patients fail a selective serotonin or norepinephrine reuptake inhibitor (SSRI or SNRI) as first-line therapy, according to President and CEO Anthony McKinney...